Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Infliximab prevents increased systolic blood pressure and upregulates the AKT/eNOS pathway in the aorta of spontaneously hypertensive rats
Author: Gazzoto, A
Kinote, A
Pereira, DJ
Renno, A
dos Santos, RC
Ferreira-Melo, SE
Velloso, LA
Bordin, S
Anhe, GF
Moreno, H
Abstract: High systolic blood pressure caused by endothelial dysfunction is a comorbidity of metabolic syndrome that is mediated by local inflammatory signals. Insulin-induced vasorelaxation due to endothelial nitric oxide synthase (eNOS) activation is highly dependent on the activation of the upstream insulin-stimulated serine/threoninekinase (AKT) and is severely impaired in obese, hypertensive rodents and humans. Neutralisation of circulating tumor necrosis factor-alpha (TNF alpha) with infliximab improves glucose homeostasis, but the consequences of this pharmacological strategy on systolic blood pressure and eNOS activation are unknown. To address this issue, we assessed the temporal changes in the systolic pressure of spontaneously hypertensive rats (SHR) treated with infliximab. We also assessed the activation of critical proteins that mediate insulin activity and TNF alpha-mediated insulin resistance in the aorta and cardiac left ventricle. Our data demonstrate that infliximab prevents the upregulation of both systolic pressure and left ventricle hypertrophy in SHR. These effects paralleled an increase in AKT/eNOS phosphorylation and a reduction in the phosphorylation of inhibitor of nuclear factor-kappa B (I kappa beta) and c-Jun N-terminal kinase (JNK) in the aorta. Overall, our study revealed the cardiovascular benefits of infliximab in SHR. In addition, the present findings further suggested that the reduction of systolic pressure and left ventricle hypertrophy by infliximab are secondary effects to the reduction of endothelial inflammation and the recovery of AKT/eNOS pathway activation. (C) 2012 Elsevier B.V. All rights reserved.
Subject: Infliximab
Insulin resistance
TNF alpha
Country: Holanda
Editor: Elsevier Science Bv
Citation: European Journal Of Pharmacology. Elsevier Science Bv, v. 700, n. 41699, n. 201, n. 209, 2013.
Rights: fechado
Identifier DOI: 10.1016/j.ejphar.2012.11.059
Date Issue: 2013
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.